What were the key findings of the LUNAR trial? - Ticiana Leal, MD

In the lunar trial led by Dr. Ticiana Leal, the fusion of TT fields therapy with conventional treatments resulted in a noteworthy upsurge in survival rates among patients battling advanced lung cancer.


In a groundbreaking lunar trial, Ticiana Leal, MD, a distinguished expert from the Winship Cancer Institute of Emory University, spearheaded a Phase three study that promised to reshape the landscape of cancer treatment. This global, randomized study aimed to scrutinize the safety and efficacy of tumor treating fields (TT fields) therapy in conjunction with standard-of-care therapies. The subjects of this trial were patients grappling with advanced non-small cell lung cancer, a cohort that had experienced progression after undergoing platinum-based chemotherapy.

In a nutshell, the primary objective was to fathom the impact of TT fields therapy, either combined with an immune checkpoint inhibitor (ICI) or docetaxel, as opposed to administering these standard therapies alone. Patients were meticulously categorized based on their ECOG performance status and followed until disease progression or the emergence of intolerable side effects.

However, for the comprehensive and detailed findings of this groundbreaking lunar trial, viewers are encouraged to watch the video presentation by Dr. Ticiana Leal herself. The trial's key discovery, particularly the significant improvement in overall survival, unveils a promising avenue in the fight against advanced non-small cell lung cancer. So, don't miss the chance to delve into the intriguing insights presented in the video.

Watch HERE the full interview with Ticiana Leal, MD